Showing 1894 results
August 2015
-
Press release
FDA expands use of Novartis drug Promacta® to include treatment of children ages 1 and older with chronic immune thrombocytopenia
New oral suspension formulation, designed for younger children with rare blood disorder, is now approved For about one in four children with ITP, the condition persists for more than 12… -
Press release
Novartis acquires all remaining rights to GSK's Ofatumumab to develop treatments for MS and other autoimmune indications
Novartis strengthens multiple sclerosis focus with the addition of Ofatumumab to leading MS portfolio which includes Gilenya and investigational treatments BAF312 and CJM112 Ofatumumab is a… -
Press release
Novartis drug Odomzo® gains EU approval for locally advanced basal cell carcinoma, providing new non-invasive therapy for patients
Approval follows positive CHMP opinion based on pivotal Phase II study showing durable objective response rate per central review of 56% in patients with laBCC[1] Basal cell carcinoma is… -
Press release
Novartis completes divestiture of influenza vaccines business to CSL Limited for USD 275 million
CSL Limited acquired influenza vaccines business of Novartis, including influenza vaccines development pipeline Basel, Switzerland, August 3, 2015 - Novartis today announced that it has completed…
July 2015
-
Story Discovery
Turning research advances into innovative medicines
A strong background in biological research prepared Daniel Rooks for his role in shaping the early clinical development of new medicines
-
Press release
Novartis partners with Phase 4 Partners and institutional investors to help create Mereo BioPharma Group Ltd
Novartis is spinning off three mid stage clinical assets to Mereo for further development in exchange for equity Novartis will have a stake in the success of the development of these compounds… -
Press release
Novartis Foundation confirms new members of its Board of trustees, including new Chairman Dr. Joerg Reinhardt
Dr. Joerg Reinhardt, Chairman of the Novartis Board of Directors, will serve as Chairman of the Foundation Board of trustees New trustees also include Professor Peter Piot of the London School… -
Press release
FDA approves Novartis drug Odomzo® (sonidegib) for locally advanced basal cell carcinoma (laBCC), a form of skin cancer
Approval is based on pivotal Phase II study in which objective response rate (ORR) in patients with laBCC was 58%; responses were durable[1] Basal cell carcinoma, the most common form of skin… -
Press release
Novartis combination therapy Tafinlar® and Mekinist® achieves important EU and US regulatory milestones
CHMP positive opinion for EU approval of Tafinlar and Mekinist combination in BRAF V600 mutation-positive melanoma, the most aggressive type of skin cancer FDA grants priority review for… -
Press release
Novartis drug Revolade® recommended by CHMP for EU approval to treat patients with severe aplastic anemia, a serious blood disorder
If approved, Revolade would be the first treatment option in its class in the EU for certain patients with SAA Approximately 40% of SAA patients unresponsive to initial immunosuppressive… -
Story From Our Labs
Five things to look for in a scientific mentor
-
Press release
Novartis delivered solid performance in the second quarter, with strong innovation and progress on new launches
Sales, core[1] operating income and core EPS grew (cc[1]) for continuing operations[2] in Q2: Net sales amounted to USD 12.7 billion (-5%, +6% cc) Operating income was USD 2.3…